Infleqtion ($INFQ, $INFQ-WT) is a quantum sensing and quantum computing pure-play that closed its SPAC merger February 13, 2026. The Q1 2026 10-Q filed May 15 is the first full quarter as a public company. Market cap ≈$3.0B fully diluted, EV ≈$2.4B against FY26 guidance of $40M revenue.

What the filing says

• Q1 revenue $9.5M (+14% YoY total). Composition: product $3.15M (-51% YoY), service $6.31M (+232%, almost entirely NASA QGGPf cost-reimbursable).
• One customer = 61% of Q1 revenue (concentration worsened — FY2025 top-two was 72%).
• Gross margin 21% (from 41% Q1 2025); service CoGS at 73% of service revenue reflects subcontractor pass-through on NASA work.
• Tiqker optical atomic clock commercial launch with Safran went live April 1, 2026 — zero disclosed Q1 product revenue attributed to the Safran channel.
• 4 material weaknesses in internal controls remain unremediated. Disclosure controls "not effective as of March 31, 2026." Remediation "may extend into 2027."
• Cash $568.6M ($85M + $484M AFS). Operating burn $19.2M Q1; interest income $3.2M. Net burn ≈$64M annualized = ≈8.9 years runway.
• Related party: former director Mr. Day resigned Q4 2025, formed Monarch Quantum, received $2.6M from INFQ in Q1 alone (27% of quarterly revenue).
• RPO $17.2M (2026) + $2.2M (2027) + $0.1M = $19.5M. Q1 actual $9.5M + 2026 RPO $17.2M = $26.7M maximum from existing contracts → $13.3M gap to $40M guidance requires new H2 contracts won AND recognized within 2026.

What the market thinks

EV/forward revenue ≈60x at $40M guidance. Stock -29% MoM, -8.6% in the print session. Management reaffirmed $40M FY26 guidance. Sell-side framing remains "post-SPAC commercial quantum pure-play with cash cushion"; the $13.3M guidance gap reads as recoverable from forthcoming wins. The tape has priced in substantial concern but not collapse.

Why the gap exists

Cross-ticker peer Q1 2026 prints (filed May 7-12) reject the sector-failure defense. IONQ printed quantum hardware $35.7M (+1067% YoY); top-2 customer concentration improved 70% → 34%. RGTI printed its first commercial QC sale at $3.05M; concentration broadened 69% → 12%. INFQ shows the opposite signature on both dimensions in the same quarter. Three reads sit in primary-source detail and have not yet been synthesized in coverage: (1) Tiqker zero-revenue Q1 detail in revenue-mix disaggregation, not headlines; (2) Monarch Quantum's 27%-of-revenue scale buried in the related-party note; (3) NVIDIA NVQLink launched October 2025 with 19 quantum hardware partners on equal footing — INFQ's Sqale integration is a CUDA-Q application available across the consortium, not exclusive validation.

Risks (ranked by impact)

1. Short squeeze / SPAC dynamics on small post-merger float. PIPE underwater at $10/share, founder shares vest at $12+ stock-price thresholds — incentive structures favor managed tape into lockup expiry Feb 13, 2027.
2. M&A optionality: $569M cash + IONQ's 6-acquisition 2025 playbook = real probability of a $20M+ INFQ-led deal within 12 months (we hold this around 25-35%).
3. Quantum thematic flows (QTUM ETF, peer momentum) lift basket regardless of fundamentals. INFQ-QTUM correlation 0.64.
4. Tiqker breakthrough order: a single Tier-1 defense customer order ≥$5M would invalidate the primary commercialization-failure leg.
5. Borrow cost unknown; short-side expression viability depends on financing terms.

Catalysts

• ~Aug 2026 — Q2 2026 10-Q + earnings call. Tiqker revenue test; material weakness disclosure update.
• Jul 31, 2026 — DARPA QBIT Stage A abstracts due.
• Dec 31, 2026 — DARPA QBI Stage A selection deadline.
• Feb 13, 2027 — SPAC founder share lockup expiry; selling-pressure tailwind.
• ~Mar 2027 — FY2026 10-K. Full-year results; material weakness remediation deadline.
• Unscheduled — Monarch Quantum coverage in financial press (60-90d half-life if a journalist picks it up); M&A announcement.

What would change our mind

• Q2 2026 product revenue ≥ $4M.
• 8-K Item 1.01 disclosing a Tiqker/Safran commercial order ≥ $2M.
• Material weakness remediation announced before the FY2026 10-K.
• Monarch Quantum relationship terminated or restructured to arm's-length pricing with disclosed methodology.
• Acquirer bid at ≥ 40% premium to current stock price.

Factor structure

Regression on 63 daily post-SPAC observations (R²=0.55) shows %Idio variance ≈ 45%, β_SPY ≈ 3.3, β_PEERS ≈ 0.44 — below the 75% idiosyncratic threshold Paleologo identifies as the line between stock-specific edge and unhedged factor exposure. INFQ-WT warrant at $5.80, strike $11.50, expires Feb 13, 2031 — essentially at-the-money, not "deep OTM" as the cumulative pre-print worldview reflected. Short window caveat: 63 obs gives wide confidence intervals on factor loadings; re-estimate after Q2 earnings.

Evidence